---
title: "FFAR1 and FFAR4 Signaling Modulates Fibroblast Responsiveness in Highly Invasive Lung Cancer Cells"
id: "pubmed-42934337"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42934337"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42934337/"
doi: "10.1007/s00418-026-02553-y"
published_at: "2026-10-27T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FFAR1 and FFAR4 Signaling Modulates Fibroblast Responsiveness in Highly Invasive Lung Cancer Cells
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42934337
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42934337/)
- **DOI:** [10.1007/s00418-026-02553-y](https://doi.org/10.1007%2Fs00418-026-02553-y)
- **Published At:** 2026-10-27T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study compared highly invasive **A549-M8** cells with parental **A549** lung cancer cells to evaluate interactions with stromal fibroblasts. - Investigators used conditioned medium from **3T3** fibroblasts and direct co-culture with **3T3** cells to assess proliferation, motility, invasion, and **cisplatin (CDDP)** sensitivity. - The invasive A549-M8 line showed greater motility and invasion and retained higher viability after **CDDP** exposure than parental A549 cells. - Co-culture with **3T3** cells increased **FFAR1** expression in both cell lines; **FFAR4** expression decreased specifically in **A549-M8** cells under co-culture conditions. - **3T3** cell supernatant stimulated proliferation and post-**CDDP** viability in **A549-M8**, whereas parental **A549** had limited responses to the same conditioned medium. - Pharmacologic modulation of free fatty acid receptors produced opposing effects: the **FFAR1** agonist **TUG-770** enhanced motility, invasion, and post-**CDDP** viability; the **FFAR4** agonist **TUG-891** suppressed those same phenotypes. - Co-culture produced reciprocal effects: **3T3** fibroblasts displayed higher motility when paired with **A549-M8** than with parental **A549** cells. - Data indicated that highly invasive cancer cells are more responsive to stromal fibroblast-derived factors and that differential **FFAR1**/**FFAR4** signaling is associated with these responses. - The abstract did not report in vivo validation, detailed molecular mechanisms linking FFAR signaling to observed phenotypes, or precise experimental dosing regimens for agonists; those details were not provided in the source.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42934337/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934337%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42934337/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42934337/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42934337/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42934337/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42934337/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42934337/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934337%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42934337%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42934337/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934337/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934337/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42934337/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42934337/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42934337/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42934337/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42934337/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42934337/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42934337/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42934337/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42934337/#grants) Title & authors Abstract Conflict of interest statement References MeSH terms Substances Grants and funding Histochem Cell Biol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Histochem+Cell+Biol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Histochem+Cell+Biol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934337/) . 2026 Oct 27;164(1):98. doi: 10.1007/s00418-026-02553-y. # Differential responsiveness to stromal fibroblasts in highly invasive lung cancer cells is associated with free fatty acid receptor 1 (FFAR1) and FFAR4 signaling [Shion Nagano](https://pubmed.ncbi.nlm.nih.gov/?term=Nagano+S&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Yuka Kusumoto](https://pubmed.ncbi.nlm.nih.gov/?term=Kusumoto+Y&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Moemi Tamura](https://pubmed.ncbi.nlm.nih.gov/?term=Tamura+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Nanami Shimomura](https://pubmed.ncbi.nlm.nih.gov/?term=Shimomura+N&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Eiki Isa](https://pubmed.ncbi.nlm.nih.gov/?term=Isa+E&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Hinata Amano](https://pubmed.ncbi.nlm.nih.gov/?term=Amano+H&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Miwa Kawamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Kawamoto+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Mizuki Ishida](https://pubmed.ncbi.nlm.nih.gov/?term=Ishida+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Mahiro Yanome](https://pubmed.ncbi.nlm.nih.gov/?term=Yanome+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Nozomi Kano](https://pubmed.ncbi.nlm.nih.gov/?term=Kano+N&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Toshifumi Tsujiuchi](https://pubmed.ncbi.nlm.nih.gov/?term=Tsujiuchi+T&cauthor_id=42934337)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#full-view-affiliation-2 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. ttujiuch@life.kindai.ac.jp.") Affiliations Expand ### Affiliations * 1 Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. * 2 Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. ttujiuch@life.kindai.ac.jp. * PMID: **42934337** * DOI: [ 10.1007/s00418-026-02553-y ](https://doi.org/10.1007/s00418-026-02553-y) Item in Clipboard # Differential responsiveness to stromal fibroblasts in highly invasive lung cancer cells is associated with free fatty acid receptor 1 (FFAR1) and FFAR4 signaling Shion Nagano et al. Histochem Cell Biol. 2026. Show details Display options Display options Format Abstract PubMed PMID Histochem Cell Biol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Histochem+Cell+Biol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Histochem+Cell+Biol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42934337/) . 2026 Oct 27;164(1):98. doi: 10.1007/s00418-026-02553-y. ### Authors [Shion Nagano](https://pubmed.ncbi.nlm.nih.gov/?term=Nagano+S&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Yuka Kusumoto](https://pubmed.ncbi.nlm.nih.gov/?term=Kusumoto+Y&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Moemi Tamura](https://pubmed.ncbi.nlm.nih.gov/?term=Tamura+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Nanami Shimomura](https://pubmed.ncbi.nlm.nih.gov/?term=Shimomura+N&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Eiki Isa](https://pubmed.ncbi.nlm.nih.gov/?term=Isa+E&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Hinata Amano](https://pubmed.ncbi.nlm.nih.gov/?term=Amano+H&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Miwa Kawamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Kawamoto+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Mizuki Ishida](https://pubmed.ncbi.nlm.nih.gov/?term=Ishida+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Mahiro Yanome](https://pubmed.ncbi.nlm.nih.gov/?term=Yanome+M&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Nozomi Kano](https://pubmed.ncbi.nlm.nih.gov/?term=Kano+N&cauthor_id=42934337)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-1 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan."), [Toshifumi Tsujiuchi](https://pubmed.ncbi.nlm.nih.gov/?term=Tsujiuchi+T&cauthor_id=42934337)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42934337/#short-view-affiliation-2 "Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. ttujiuch@life.kindai.ac.jp.") ### Affiliations * 1 Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. * 2 Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan. ttujiuch@life.kindai.ac.jp. * PMID: **42934337** * DOI: [ 10.1007/s00418-026-02553-y ](https://doi.org/10.1007/s00418-026-02553-y) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Solid tumors contain cancer cells and stromal cells that interact within the tumor microenvironment and influence malignant progression. However, whether the interaction between cancer cells and stromal cells changes as the malignant potential of cancer cells increases remains unclear. This study investigated the interaction between lung cancer cells and fibroblasts and examined the involvement of free fatty acid receptors (FFARs). Highly invasive A549-M8 cells derived from parental A549 cells were compared with A549 cells. Cells were cultured with 3T3 fibroblast supernatant or co-cultured with 3T3 cells, and proliferation, motility, invasion, and cisplatin (CDDP) sensitivity were evaluated. The effects of FFAR1 and FFAR4 activation were assessed using the respective agonists TUG-770 and TUG-891. A549-M8 cells exhibited greater motility and invasion and higher cell viability following CDDP treatment than A549 cells. Co-culture with 3T3 cells increased FFAR1 expression in both cell types and reduced FFAR4 expression in A549-M8 cells. 3T3 cell supernatant increased A549-M8 cell proliferation and cell viability following CDDP treatment, whereas these responses were limited in A549 cells. TUG-770 enhanced motility, invasion, and cell viability following CDDP treatment, whereas TUG-891 suppressed motility, invasion, and cell viability following CDDP treatment. Notably, the responses to 3T3 cells were stronger in A549-M8 cells, and 3T3 cell motility was also higher when co-cultured with A549-M8 cells than with A549 cells. These findings suggest that highly invasive A549-M8 cells exhibit greater responsiveness to stromal fibroblast-derived factors than parental A549 cells, while co-culture experiments indicate reciprocal effects between A549-M8 and 3T3 cells. FFAR1 and FFAR4 signaling is associated with these differential responses. **Keywords:** Fibroblasts; Free fatty acid receptors; Invasion; Lung cancer cells; Motility. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. ## References 1. 1. Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K (2018) Fibroblast in the tumor microenvironment: shield or spear? Int J Mol Sci 19:1532 - [DOI](https://doi.org/10.3390/ijms19051532) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/29883428/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/5983719/) 2. 1. Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125:5591–5596 - [DOI](https://doi.org/10.1242/jcs.116392) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/23420197/) 3. 1. Bejarano L, Jordāo MJC, Joyce JA (2021) Therapeutic targeting of the tumor microenvironment. Cancer Discov 11:933–959 - [DOI](https://doi.org/10.1158/2159-8290.cd-20-1808) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/33811125/) 4. 1. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, Jenkins L, Zaibi M, Stocker CJ, Ullich S, Kostenis E, Kassack MU, Milligan G, Cawthorme MA, Ulven T (2013) Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med Che Lett 4:441–445 - [DOI](https://doi.org/10.1021/ml4000673) 5. 1. de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41:374–403 - [DOI](https://doi.org/10.1016/j.ccell.2023.02.016) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/36917948/) Show all 24 references ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [
## Related Clinical Research

- [Machine Learning–Defined LUAD Subtypes and RRM2 Linked to Cisplatin Resistance](https://medichelpline.com/clinical-feed/pubmed-42958928.md) (DOI: 10.1111/1759-7714.70407)
- [TRPV1-targeted Fe-phenolate (FeOLDA) induces apoptosis and ferroptosis in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42411334.md) (DOI: 10.1039/d6bm00434b)
- [Pollen size shifts after whole genome duplication in autotetraploids](https://medichelpline.com/clinical-feed/biorxiv-17-biased-evolution-of-pollen-size-after-whole-genome-duplication.md)
- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.